

Cabozantinib Development Program

Discovered by Exelixis, and the focus of our development and commercialization efforts, Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET and is recognized for its potential to treat a wide variety of cancers.

Filter by Therapeutic Area

- ☐ Adrenal Tumors
- ☐ Adrenocortical Carcinoma
- ☐ Any GU Tumors
- ☐ Bladder Cancer
- ☐ Breast Cancer
- ☐ Colorectal Cancer (CRC)
- ☐ Differentiated Thyroid Cancer (DTC)
- ☐ Endometrial Cancer
- ☐ Esophageal Cancer
- ☐ Gastroesophageal Cancer
- ☐ Gastrointestinal (GI) Cancers
- ☐ Gastrointestinal Stromal Tumors (GIST)
- ☐ Genitourinary (GU) Cancers
- ☐ Gynecologic Cancers
- ☐ Head and Neck Cancer
- ☐ Hepatocellular Carcinoma (HCC)
- ☐ Lung Cancer
- ☐ Melanoma
- ☐ Mesothelioma
- ☐ Multiple Myeloma
- ☐ Multiple Solid Tumor Types
- ☐ Neuroendocrine Tumors (NET) & Carcinoid
- ☐ Neurofibroma
- ☐ Pediatric Sarcoma
- ☐ Prostate Cancer
- ☐ Rare GU Tumors
- ☐ Renal Cell Carcinoma (RCC)
- ☐ Sarcoma
- ☐ Squamous Cell Carcinoma
- ☐ Thyroid Cancer
- ☐ Urothelial Carcinoma (UIC)

Exelixis-Sponsored Trial

Calithera-Sponsored Trial

Roche-Sponsored Trial

Bristol Myers Squibb-Sponsored Trial

Investigator-Sponsored Trial

Collaboration with NCI's Cancer Therapy Evaluation Program

Sponsored by the European Organization for Research and Treatment of Cancer (EORTC)

Clear Filters

Genitourinary (GU) Cancers

|                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COSMIC-021: Cabozantinib</b><br>(Advanced UIC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>                                                                | <b>Cyto-KiK: CYTO Reductive Surgery followed by Cabozantinib + Nivolumab</b><br>(Metastatic RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04322955">https://clinicaltrials.gov/ct2/show/NCT04322955</a>                                                                                          | <b>CONTACT-03: Cabozantinib + Atezolizumab vs. Cabozantinib</b><br>(Advanced RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03932628">https://clinicaltrials.gov/ct2/show/NCT03932628</a>                                                    |
| <b>Urothelial Carcinoma</b>                                                                                                                                                                                                                                            | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                                                                       | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                  |
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(Advanced RCC, Advanced UIC & CRPC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>                            | <b>ABATE: Cabozantinib + Atezolizumab</b><br>(Muscle-Invasive Bladder Cancer)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0488779">https://clinicaltrials.gov/ct2/show/NCT0488779</a>                                                                                                               | <b>CONTACT-04: Cabozantinib + Atezolizumab vs. Cabozantinib</b><br>(Metastatic, Castrate-Resistant PC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04464977">https://clinicaltrials.gov/ct2/show/NCT04464977</a>                               |
| <b>Renal Cell Carcinoma / Urothelial Carcinoma / Prostate Cancer</b>                                                                                                                                                                                                   | <b>Bladder Cancer</b>                                                                                                                                                                                                                                                                                                                             | <b>Prostate Cancer</b>                                                                                                                                                                                                                                                                       |
| <b>Cabozantinib + Docetaxel + Prednisone vs. Docetaxel + Prednisone</b><br>(Metastatic, Castrate-Resistant PC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT01683994">https://clinicaltrials.gov/ct2/show/NCT01683994</a> | <b>PemCabo: Cabozantinib + Pembrolizumab</b><br>(Metastatic UC Ineligible for Cisplatin)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03554504">https://clinicaltrials.gov/ct2/show/NCT03554504</a>                                                                                                  | <b>COSMIC-313: Cabozantinib + Nivolumab + Ipilimumab</b><br>(First-line Advanced or Metastatic RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03937219">https://clinicaltrials.gov/ct2/show/NCT03937219</a>                                  |
| <b>Prostate Cancer</b>                                                                                                                                                                                                                                                 | <b>Bladder Cancer / Urothelial Carcinoma</b>                                                                                                                                                                                                                                                                                                      | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                  |
| <b>Cabozantinib + Nivolumab + Ipilimumab</b><br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02496208">https://clinicaltrials.gov/ct2/show/NCT02496208</a>                                                                   | <b>CANTATA: Cabozantinib + C9-B39</b><br>(Advanced or Metastatic RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03942617">https://clinicaltrials.gov/ct2/show/NCT03942617</a>                                                                                                                     | <b>CheckMate 9ER: Cabozantinib + Nivolumab vs. Sunitinib</b><br>(First-line Advanced RCC)<br>Status: Phase 3, pivotal trial<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03701077">https://clinicaltrials.gov/ct2/show/NCT03701077</a>          |
| <b>Any GU Tumors</b>                                                                                                                                                                                                                                                   | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                                                                       | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                        | <b>Radical: Cabozantinib + Radium-223 Dichloride</b><br>(Advanced RCC with Bone Metastasis)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0073223">https://clinicaltrials.gov/ct2/show/NCT0073223</a>                                                                                                 | <b>PDIGREE: Nivolumab + Ipilimumab followed by Cabozantinib + Nivolumab vs. Nivolumab</b><br>(First-line Advanced or Metastatic RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03793166">https://clinicaltrials.gov/ct2/show/NCT03793166</a> |
|                                                                                                                                                                                                                                                                        | <b>SPARC: Cabozantinib vs. Immediate Prostatectomy</b><br>(High-Risk Prostate Cancer)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03964537">https://clinicaltrials.gov/ct2/show/NCT03964537</a>                                                                                                     | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                        | <b>ICONIC: Cabozantinib + Nivolumab + Ipilimumab</b><br>(Rare GU Tumors)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03663827">https://clinicaltrials.gov/ct2/show/NCT03663827</a><br><a href="https://clinicaltrials.gov/ct2/show/NCT03663827">https://clinicaltrials.gov/ct2/show/NCT03663827</a> |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>Cabozantinib + Nivolumab</b><br>(Advanced or Metastatic Non-clear Cell RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03555992">https://clinicaltrials.gov/ct2/show/NCT03555992</a>                                                                                                            |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>PAPMET: Cabozantinib vs. Sunitinib</b><br>(Metastatic, Papillary RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02761057">https://clinicaltrials.gov/ct2/show/NCT02761057</a>                                                                                                                  |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>CABOSUN II: Cabozantinib vs. Sunitinib</b><br>(Variant Histology RCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03353158">https://clinicaltrials.gov/ct2/show/NCT03353158</a>                                                                                                                  |                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                        | <b>Renal Cell Carcinoma</b>                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                              |

Gastrointestinal (GI) Cancers

|                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>CAMILLA: Cabozantinib + Durvalumab</b><br>(Advanced CRC & HCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03539832">https://clinicaltrials.gov/ct2/show/NCT03539832</a>                                                                                                                      | <b>CheckMate 040 Subgroup: Cabozantinib + Nivolumab + Ipilimumab</b><br>(First-line and Previously Treated Advanced HCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03658878">https://clinicaltrials.gov/ct2/show/NCT03658878</a> | <b>COSMIC-312: Cabozantinib + Atezolizumab vs. Sorafenib vs. Cabozantinib</b><br>(First-line Advanced HCC)<br>Status: Phase 3, pivotal trial<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03759591">https://clinicaltrials.gov/ct2/show/NCT03759591</a> |
| <b>Colorectal Cancer / Hepatocellular Carcinoma</b>                                                                                                                                                                                                                                                                                            | <b>Hepatocellular Carcinoma</b>                                                                                                                                                                                                                                                  | <b>Hepatocellular Carcinoma</b>                                                                                                                                                                                                                                                                      |
| <b>Cabozantinib + Nivolumab</b><br>(Neoadjuvant, Locally Advanced HCC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0299946">https://clinicaltrials.gov/ct2/show/NCT0299946</a>                                                                                                                   | <b>Cabozantinib</b><br>(Refractory Metastatic CRC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03542677">https://clinicaltrials.gov/ct2/show/NCT03542677</a>                                                                       |                                                                                                                                                                                                                                                                                                      |
| <b>Hepatocellular Carcinoma</b>                                                                                                                                                                                                                                                                                                                | <b>Colorectal Cancer</b>                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                      |
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(HCC & GIC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>                                                                                                                            | <b>CABOGIST: Cabozantinib</b><br>(Metastatic GIST)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02169578">https://clinicaltrials.gov/ct2/show/NCT02169578</a>                                                                       |                                                                                                                                                                                                                                                                                                      |
| <b>Colorectal Cancer / Hepatocellular Carcinoma</b>                                                                                                                                                                                                                                                                                            | <b>Gastrointestinal Stromal Tumor</b>                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                      |
| <b>CaboMab: Cabozantinib + Panitumumab</b><br>(pRAS Wild-Type Metastatic CRC & IRE1 Amplified Metastatic CRC)<br>Patients with MET amplification will receive cabozantinib monotherapy<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02008383">https://clinicaltrials.gov/ct2/show/NCT02008383</a> | <b>Cabozantinib + Erlotinib</b><br>(Metastatic Pancreatic Adenocarcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03136246">https://clinicaltrials.gov/ct2/show/NCT03136246</a>                                                |                                                                                                                                                                                                                                                                                                      |
| <b>Colorectal Cancer</b>                                                                                                                                                                                                                                                                                                                       | <b>Pancreatic Cancer</b>                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                      |

Thyroid Cancer

|                                                                                                                                                                                                               |                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(DTC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a> | <b>Cabozantinib</b><br>(First-line, RAI-refractory DTC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02042660">https://clinicaltrials.gov/ct2/show/NCT02042660</a> | <b>COSMIC-311: Cabozantinib vs. Placebo</b><br>(RAI-refractory DTC Previously Treated with VEGFR-targeted Therapy)<br>Status: Phase 3, pivotal trial initiated in October 2018<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03690388">https://clinicaltrials.gov/ct2/show/NCT03690388</a> |
| <b>Differentiated Thyroid Cancer</b>                                                                                                                                                                          | <b>Differentiated Thyroid Cancer</b>                                                                                                                                                                            | <b>Differentiated Thyroid Cancer</b>                                                                                                                                                                                                                                                                                                   |

Lung Cancer

|                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>COSMIC-021: Cabozantinib</b><br>(NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>                | <b>Cabozantinib vs. Cabozantinib + Nivolumab vs. Chemotherapy</b><br>(Previously Treated Non-Squamous NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04300007">https://clinicaltrials.gov/ct2/show/NCT04300007</a> | <b>CONTACT-01: Cabozantinib + Atezolizumab vs. Docetaxel</b><br>(Metastatic NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04747438">https://clinicaltrials.gov/ct2/show/NCT04747438</a> |
| <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                               | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                                                    | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                          |
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a> | <b>Cabozantinib + Nivolumab + Ipilimumab and Cabozantinib + Nivolumab</b><br>(NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04055643">https://clinicaltrials.gov/ct2/show/NCT04055643</a>                         |                                                                                                                                                                                                                                            |
| <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                               | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Cabozantinib</b><br>(With Brain Metastases with and without c-MET Amplification)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0312558">https://clinicaltrials.gov/ct2/show/NCT0312558</a>                            |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Cabozantinib</b><br>(Molecular Alterations in RET, ROS1, MET, AXL, or NTRK1)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03639508">https://clinicaltrials.gov/ct2/show/NCT03639508</a>                              |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Nivolumab vs. Cabozantinib + Nivolumab vs. Cabozantinib + Nivolumab + Ipilimumab</b><br>(NSCLC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03468385">https://clinicaltrials.gov/ct2/show/NCT03468385</a>           |                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                 | <b>Non-Small Cell Lung Cancer</b>                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                            |

Gynecologic Cancers

|                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                             |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(EC, Ovarian Cancer & Breast Cancer)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a> | <b>Nivolumab + Cabozantinib</b><br>(Advanced or Metastatic EC)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03637794">https://clinicaltrials.gov/ct2/show/NCT03637794</a>                                                      |  |
| <b>Breast Cancer / Ovarian Cancer / Endometrial Cancer</b>                                                                                                                                                                                   | <b>Endometrial Cancer</b>                                                                                                                                                                                                                                                   |  |
|                                                                                                                                                                                                                                              | <b>Cabozantinib</b><br>(Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Endometrium)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02315430">https://clinicaltrials.gov/ct2/show/NCT02315430</a>               |  |
|                                                                                                                                                                                                                                              | <b>Ovarian Cancer</b>                                                                                                                                                                                                                                                       |  |
|                                                                                                                                                                                                                                              | <b>Cabozantinib + Trastuzumab</b><br>(With Brain Metastases)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02605931">https://clinicaltrials.gov/ct2/show/NCT02605931</a>                                                        |  |
|                                                                                                                                                                                                                                              | <b>Breast Cancer</b>                                                                                                                                                                                                                                                        |  |
|                                                                                                                                                                                                                                              | <b>Cabozantinib + Fulvestrant</b><br>(Metastatic, Hormone-receptor-positive Breast Cancer with involvement of bone)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03404947">https://clinicaltrials.gov/ct2/show/NCT03404947</a> |  |
|                                                                                                                                                                                                                                              | <b>Breast Cancer</b>                                                                                                                                                                                                                                                        |  |
|                                                                                                                                                                                                                                              | <b>Cabozantinib + Nivolumab</b><br>(Metastatic, Triple-negative Breast Cancer)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03368686">https://clinicaltrials.gov/ct2/show/NCT03368686</a>                                      |  |
|                                                                                                                                                                                                                                              | <b>Breast Cancer</b>                                                                                                                                                                                                                                                        |  |

Neuroendocrine Tumors (NET) & Carcinoid

|                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cabozantinib + Nivolumab + Ipilimumab</b><br>(Poorly Differentiated Neuroendocrine Carcinomas)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04079772">https://clinicaltrials.gov/ct2/show/NCT04079772</a> | <b>CABINET: Cabozantinib vs. Placebo</b><br>(Advanced Neuroendocrine Tumors After Progression on Everolimus)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03759320">https://clinicaltrials.gov/ct2/show/NCT03759320</a> |
| <b>NET &amp; Carcinoid</b>                                                                                                                                                                                                                                | <b>NET &amp; Carcinoid</b>                                                                                                                                                                                                                                           |
| <b>Cabozantinib + Nivolumab</b><br>(Advanced Carcinoid Tumors)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04197310">https://clinicaltrials.gov/ct2/show/NCT04197310</a>                                    |                                                                                                                                                                                                                                                                      |
| <b>NET &amp; Carcinoid</b>                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                      |
| <b>Cabozantinib</b><br>(Advanced Metastatic NET & Advanced Carcinoid)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04660346">https://clinicaltrials.gov/ct2/show/NCT04660346</a>                             |                                                                                                                                                                                                                                                                      |
| <b>NET &amp; Carcinoid</b>                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                      |

Adrenocortical Carcinoma

|                                                                                                                                                                                                                                  |  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>Cabozantinib</b><br>(Metastatic Pheochromocytomas and Paragangliomas)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03028433">https://clinicaltrials.gov/ct2/show/NCT03028433</a> |  |
| <b>Adrenal Tumors</b>                                                                                                                                                                                                            |  |
| <b>Cabozantinib</b><br>(Metastatic Adrenocortical Carcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03370778">https://clinicaltrials.gov/ct2/show/NCT03370778</a>             |  |
| <b>Adrenal Tumors</b>                                                                                                                                                                                                            |  |

Sarcoma

|                                                                                                                                                                                                                                                                        |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>Cabozantinib + Radiation Therapy</b><br>(Sarcomas of the Extremities)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04202029">https://clinicaltrials.gov/ct2/show/NCT04202029</a>                                       |  |
| <b>Sarcoma</b>                                                                                                                                                                                                                                                         |  |
| <b>Cabozantinib + Temozolomide</b><br>(Inoperable or Metastatic Leiomyosarcoma and other Soft Tissue Sarcomas)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04200443">https://clinicaltrials.gov/ct2/show/NCT04200443</a> |  |
| <b>Sarcoma</b>                                                                                                                                                                                                                                                         |  |
| <b>Cabozantinib vs. Placebo</b><br>(High-Grade Uterine Sarcoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03793933">https://clinicaltrials.gov/ct2/show/NCT03793933</a>                                                |  |
| <b>Sarcoma</b>                                                                                                                                                                                                                                                         |  |
| <b>Cabozantinib</b><br>(Metastatic Soft Tissue Sarcoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT01755919">https://clinicaltrials.gov/ct2/show/NCT01755919</a>                                                        |  |
| <b>Sarcoma</b>                                                                                                                                                                                                                                                         |  |
| <b>CABONE: Cabozantinib</b><br>(Chondrosarcoma and Ewing Sarcoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02245605">https://clinicaltrials.gov/ct2/show/NCT02245605</a>                                              |  |
| <b>Sarcoma</b>                                                                                                                                                                                                                                                         |  |
| <b>Cabozantinib in Plexiform Neurofibromas</b><br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02100736">https://clinicaltrials.gov/ct2/show/NCT02100736</a>                                                                 |  |
| <b>Neurofibroma</b>                                                                                                                                                                                                                                                    |  |

Gastroesophageal Cancer

|                                                                                                                                                                                                                                                                        |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>CAMILLA: Cabozantinib + Durvalumab</b><br>(Advanced Gastric, Gastroesophageal or Esophageal Adenocarcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03539832">https://clinicaltrials.gov/ct2/show/NCT03539832</a> |  |
| <b>Gastroesophageal Cancer / Esophageal Cancer</b>                                                                                                                                                                                                                     |  |
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(Gastric or Gastroesophageal Junction Adenocarcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>          |  |
| <b>Gastroesophageal Cancer</b>                                                                                                                                                                                                                                         |  |

Head and Neck Cancer

|                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cabozantinib + Cetuximab</b><br>(Recurrent Metastatic Squamous Cell Carcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT01566782">https://clinicaltrials.gov/ct2/show/NCT01566782</a> | <b>Cabozantinib + Pembrolizumab</b><br>(Recurrent Metastatic Squamous Cell Carcinoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03648218">https://clinicaltrials.gov/ct2/show/NCT03648218</a> |
| <b>Squamous Cell Carcinoma</b>                                                                                                                                                                                                            | <b>Squamous Cell Carcinoma</b>                                                                                                                                                                                                                |
| <b>COSMIC-021: Cabozantinib + Atezolizumab</b><br>(Head and Neck Cancer)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT0370960">https://clinicaltrials.gov/ct2/show/NCT0370960</a>            |                                                                                                                                                                                                                                               |
| <b>Head and Neck Cancer</b>                                                                                                                                                                                                               |                                                                                                                                                                                                                                               |

Melanoma

|                                                                                                                                                                                                                                           |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>Cabozantinib + Pembrolizumab</b><br>(Advanced Metastatic Melanoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03957951">https://clinicaltrials.gov/ct2/show/NCT03957951</a>             |  |
| <b>Melanoma</b>                                                                                                                                                                                                                           |  |
| <b>Cabozantinib + Nivolumab + Ipilimumab</b><br>(Unresectable, Advanced Melanoma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04091790">https://clinicaltrials.gov/ct2/show/NCT04091790</a> |  |
| <b>Melanoma</b>                                                                                                                                                                                                                           |  |

Multiple Solid Tumor Types

|                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cabozantinib + Pemtrexed</b><br>(Advanced Non-Squamous NSCLC, UC, and Advanced Malignant Mesothelioma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT04073338">https://clinicaltrials.gov/ct2/show/NCT04073338</a> | <b>Cabozantinib</b><br>(Patients with Brain Bone Metastases, Non-Breast, Non-Prostate)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03888821">https://clinicaltrials.gov/ct2/show/NCT03888821</a> |
| <b>Non-Small Cell Lung Cancer / Urothelial Carcinoma / Mesothelioma</b>                                                                                                                                                                                           | <b>Multiple Solid Tumor Types</b>                                                                                                                                                                                                              |
| <b>Cabozantinib</b><br>(in Patients with MM)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT01822522">https://clinicaltrials.gov/ct2/show/NCT01822522</a>                                                              |                                                                                                                                                                                                                                                |
| <b>Multiple Solid Tumor Types</b>                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                |

Multiple Myeloma

|                                                                                                                                                                                                                                                       |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| <b>Cabozantinib + Carfilzomib</b><br>(Refractory Multiple Myeloma)<br>Status: Phase 1/2 trial<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03201250">https://clinicaltrials.gov/ct2/show/NCT03201250</a> |  |
| <b>Multiple Myeloma</b>                                                                                                                                                                                                                               |  |

Pediatric Cancer

|                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cabozantinib + Retinoic Acid</b><br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03616995">https://clinicaltrials.gov/ct2/show/NCT03616995</a>                                                    | <b>Cabozantinib in Plexiform Neurofibromas</b><br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02107936">https://clinicaltrials.gov/ct2/show/NCT02107936</a>                                  |
| <b>Pediatric Multiple Tumor Types</b>                                                                                                                                                                                                          | <b>Pediatric Neurofibroma</b>                                                                                                                                                                                                           |
| <b>Cabozantinib</b><br>(Children & Adolescents with Solid Tumors Including CNS Tumors)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT07209435">https://clinicaltrials.gov/ct2/show/NCT07209435</a> | <b>Cabozantinib</b><br>(High-Grade Pediatric Glioma)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT03855324">https://clinicaltrials.gov/ct2/show/NCT03855324</a>                            |
| <b>Pediatric Multiple Tumor Types</b>                                                                                                                                                                                                          | <b>Pediatric Glioma</b>                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                | <b>CABONE: Cabozantinib</b><br>(Chondrosarcoma and Ewing Sarcoma: Patients 12+)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02245605">https://clinicaltrials.gov/ct2/show/NCT02245605</a> |
|                                                                                                                                                                                                                                                | <b>Pediatric Sarcoma</b>                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                | <b>Cabozantinib</b><br>(Refractory Sarcoma, Wilms Tumor, Other Rare Tumors)<br>For more information, please visit:<br><a href="https://clinicaltrials.gov/ct2/show/NCT02867932">https://clinicaltrials.gov/ct2/show/NCT02867932</a>     |
|                                                                                                                                                                                                                                                | <b>Pediatric Multiple Tumor Types</b>                                                                                                                                                                                                   |

Other Partnered Compounds

We are also advancing cancer treatment through collaborations.

LEARN MORE >